# Cytokine Release Syndrome > Cytokine release syndrome for NEET-PG Medicine: CAR T-cell timing, ASTCT grading, tocilizumab, steroids and ICANS with the ICE score. - Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/cytokine-release-syndrome - Exam / course: NEET-PG · Subject: Medicine - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Cytokine Release Syndrome", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/cytokine-release-syndrome ## Direct answer Fever with hypotension and hypoxia appearing three to seven days after CAR T-cell infusion — or within days of blinatumomab, and occasionally other monoclonals — is cytokine release syndrome: massive interleukin-6, TNF-alpha and interferon-gamma release from activated immune effector cells, producing capillary leak, vasodilatory shock and end-organ dysfunction that mimics sepsis. Grading by the ASTCT criteria runs from grade 1 (fever alone), through grade 2 (fluid-responsive hypotension, low-flow oxygen requirement), to grade 3 (vasopressors, high-flow oxygen) and grade 4 (life-threatening instability). Tocilizumab, the anti-interleukin-6-receptor antibody, is the licensed antidote, given early for grade 2 and above with corticosteroids added for grade 3-4 and whenever neurotoxicity appears; cultures are drawn in parallel because infection remains the great imitator. ## What you must remember - **Triggers and timing:** CAR T cells — fever typically day 3-7 after infusion; blinatumomab and high-grade lymphocyte-depleting antibodies — within the first days, mitigated by step-up dosing. - **Mediators:** IL-6 drives fever and vascular leak — hence tocilizumab; TNF-alpha and interferon-gamma amplify the storm; ferritin, CRP and falling albumin track severity. - **ASTCT grading:** grade 1 fever with no hypotension or hypoxia; grade 2 hypotension responding to fluids and hypoxia needing low-flow oxygen; grade 3 vasopressor-requiring hypotension and/or high-flow oxygen; grade 4 life-threatening cardiopulmonary compromise. - **Tocilizumab dosing:** 8 mg/kg intravenously (many protocols allow repeat doses at eight-hourly intervals), licensed for CAR T-cell-associated CRS after demonstration in pivotal trials. - **Steroids:** second-line in pure CRS to avoid blunting the anti-tumour effect, but first-line when neurotoxicity coexists or grade 4 physiology threatens. - **ICANS:** CAR T-cell-related encephalopathy — confusion, aphasia, tremor, seizures, cerebral oedema — scored by the ICE tool, worsened by severe CRS, treated with dexamethasone or methylprednisolone. - **Differential discipline:** sepsis, tumour lysis syndrome and haemophagocytic lymphohistiocytosis overlap almost perfectly — cultures, urate, LDH and ferritin adjudicate while treatment proceeds. ## Managing a fever on day 4 after CAR T infusion A 19-year-old with relapsed B-cell acute lymphoblastic leukaemia develops temperature 39.2 degrees on day 4 after CD19-directed CAR T-cell therapy. First act: vitals establish the grade — blood pressure holds with a litre of crystalloid, oxygen saturation is 93 percent on nasal specs at 2 litres, so this is grade 2. Second act: infection screen in parallel — blood, urine and line cultures, chest radiograph — but antimicrobial treatment waits on nothing; febrile neutropenia cover starts because the two diagnoses coexist comfortably. Third act: tocilizumab 8 mg/kg intravenously, with paracetamol and fluid support; antihistamines and steroids pre-empted nothing here. Fourth act: the next 12 hours decide the trajectory — vasopressor requirement upgrades to grade 3 and adds dexamethasone plus intensive care; resolution instead downgrades care. Throughout, hourly neurological observation with the ICE score catches the whispered word-finding difficulty that signals ICANS, treated decisively with steroids rather than observed hopefully. The reasoning to articulate: why tocilizumab before steroids in isolated CRS — IL-6 blockade controls the syndrome without deleting the engineered T cells, whereas early high-dose steroids can blunt the graft-versus-tumour effect that is the whole point of the therapy. ## The Indian perspective CAR T-cell therapy has crossed from trial to approved use in India, with indigenous CD19 constructs reported and tertiary centres in metros delivering them — which converts CRS from an examination curiosity into district-hospital reality, since patients return home during follow-up and may re-present locally. Practical Indian points: tocilizumab became familiar during COVID-19, so intensivists have handled the drug, but its cost still rationises use; a febrile post-CAR-T patient in a monsoon-season district hospital carries dengue, typhoid and sepsis in the differential alongside CRS, so the ASTCT grade must be applied after infection data, not before; and any centre administering immune effector therapies must stock tocilizumab and write the escalation pathway before the first infusion, not after the first emergency. ## Frequently asked questions ### Which drug is licensed for CAR T-cell-associated cytokine release syndrome? Tocilizumab, an interleukin-6 receptor blocker, 8 mg/kg intravenously with repeat dosing permitted — the first-line antidote for grade 2 and above. ### When does CRS typically begin after CAR T-cell infusion? Around day 3-7 for most constructs, earlier with some products and with blinatumomab — timing itself is a diagnostic clue. ### What is ICANS and how is it assessed? Immune effector cell-associated neurotoxicity — confusion, aphasia, seizures, cerebral oedema — graded by the ICE (immune effector cell-associated encephalopathy) score. ### What defines ASTCT grade 3 CRS? Hypotension requiring vasopressors and/or hypoxia needing high-flow oxygen, mandating intensive care and steroid addition. ### Why do steroids trail tocilizumab in isolated CRS? High-dose steroids suppress the engineered T cells and may blunt anti-tumour efficacy, so they are reserved for grade 3-4 disease and neurotoxicity.